Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: Prevalence, risk factors and virological outcome

Valerio Tozzi, Mauro Zaccarelli, Sandro Bonfigli, Patrizia Lorenzini, Giuseppina Liuzzi, Maria Paola Trotta, Federica Forbid, Caterina Gori, Ada Bertoli, Rita Bellagamba, Pasquale Narciso, Carlo Federico Perno, Andrea Antinori

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Drug-class-wide resistance (DCWR) to antiretrovirals substantially reduces treatment options. Methods: A database of 602 patients failing highly active antiretroviral therapy (HAART) undergoing genotypic resistance test (GRT) was analysed. DCWR was defined according to the International AIDS Society consensus. A multiple logistic regression model was built to define factors significantly associated with DCWR and to assess virological response to salvage regimens. Results: NRTI DCWR was observed in 28.5% of 592 NRTI-exposed patients, NNRTI DCWR in 57.7% of 284 NNRTI exposed patients, PI DCWR in 19.9% of 412 PI exposed patients, and three-class resistance in 21.4% of 112 three-class-exposed patients. The prevalence of NRTI and PI DCWR increased significantly by year of exposure to the same class from 8.9% (4 years) and from 1.2% (4 years), respectively (P4 years; P

Original languageEnglish
Pages (from-to)553-560
Number of pages8
JournalAntiviral Therapy
Volume11
Issue number5
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: Prevalence, risk factors and virological outcome'. Together they form a unique fingerprint.

Cite this